Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01035879
Recruitment Status : Completed
First Posted : December 21, 2009
Last Update Posted : April 17, 2015
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : August 2010
  Actual Study Completion Date : August 2010
  Certification/Extension First Submitted : February 16, 2015